It is quite unusual to see a stock close to (i.e. perhaps only weeks away from) a significant approval trade at close to its 5-year low. Obviously the recent CR/share placement is a significant factor. Still, if all goes well with the FDA approval, being able to buy in at close to the lowest SP presents an extraordinary oportunity, IMO, given the potential upside. GLTA
Nova Eye Medical (EYE) Discussion, page-37
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $62.91M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 28.0¢ | 26.5¢ | $223.0K | 814.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 80000 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 92999 | 2 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
0.000 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| 27.5¢ | 28.0¢ | 26.5¢ | 240574 | ||
| Last updated 15.47pm 29/04/2024 ? | |||||
| EYE (ASX) Chart |